Tamoxifen Can Halve Risk of Breast Cancer Returning: Study

UK scientists have discovered that breast cancer patients who took the drug tamoxifen for 10 years halved the risk of the disease returning, Birmingham Mail reported.

As quoted in the market news:

The study, carried out at the University of Birmingham and funded by Cancer Research UK, shows that sufferers who take tamoxifen for longer than the recommended five years are better protected against a further attack and are less likely to die from the disease.

The “aTTom” study looked at almost 7,000 women with breast cancer who, after five years of taking the drug, either continued taking the drug for another five years or stopped treatment.

Click here to read the full news story by the Birmingham Mail